KLARICID IV PDF
Klaricid IV mg (PL /, Abbott Laboratories Ltd). No new or unexpected safety concerns arose from this application and it was therefore judged that. Indications, side effects, contraindications and other prescribing information for Klaricid IV on MIMS. Clarithromycin is indicated in: Lower respiratory tract infection: acute and chronic bronchitis and pneumonia;; Upper respiratory tract infection: sinusitis and.
|Published (Last):||20 May 2007|
|PDF File Size:||20.17 Mb|
|ePub File Size:||15.8 Mb|
|Price:||Free* [*Free Regsitration Required]|
If superinfections occur, appropriate therapy should be instituted. Overview Klaricid Iv Injection is used for Acute bacterial exacerbation of chronic ivvAcute maxillary sinusitisCommunity-acquired pneumonia, Pharyngitis and tonsillitisSkin and skin structure infections, Acute otitis mediaMycobacterial infectionsHelicobacter pylori infection and other conditions.
These adverse reactions are usually mild in intensity and are consistent with the known safety profile of macrolide antibiotics. This medicinal product contains less than 23mg sodium 1mmol per mg i.
How to store Klaricid IV Keep out of the sight and reach of children Do not use after the expiry date on the carton and vial. Serum level determinations are recommended for these drugs when administered concomitantly with clarithromycin.
Klaricid-I.V mg Inf – Clarithromycin – Price in Pakistan –
Sign Up Log In Cancel. Patients receiving terfenadine who have pre-existing cardiac abnormalities or electrolyte disturbances. The frequency of this side effect is not known cannot be estimated from the available data.
Show all parts of this monograph Indications and dose Unlicensed use Cautions Interactions Side-effects Pregnancy Breast feeding Klaaricid impairment Renal impairment Directions for administration Patient and carer advice Profession specific information Medicinal forms Indications and dose Respiratory-tract infectionsMild to moderate skin and soft-tissue infectionsOtitis media By mouth using immediate-release medicines For Child 1 month—11 years body-weight up to 8 kg 7.
The activity of clarithromycin against H. The original can be viewed in PDF format using the link above. It may harm them, even if their symptoms are the same as yours.
Medicines Klabex mg 10pcs. Pseudomembranous colitis has been reported with nearly all antibacterial agents, including macrolides, and may range in severity from mild to life-threatening. Treatment with antibacterial agents alters the normal flora of the colon, which may lead to overgrowth of C. Localized infections due ov Mycobacterium chelonae, Mycobacterium fortuitum, or Mycobacterium kansasii Pack Size: Careful monitoring of glucose is recommended. Lower respiratory tract infection: Clarithromycin may be used in neonates and children in appropriate doses.
Healthcare professionals are asked to report any suspected adverse reactions via the Yellow Card Scheme at: This includes any possible side effects not listed in this leaflet. For Child 1 month—11 years body-weight 8—11 kg Contents of the pack and other information. Therefore, children under 12 years of age should use clarithromycin paediatric suspension. Klaricid IV may make you feel dizzy or drowsy. The potential for dizziness, vertigo, confusion and disorientation, which may occur with the medication, should be taken into account before patients drive or use machines.
If treatment with clarithromycin cannot be avoided, therapy with lovastatin or simvastatin must be suspended during the course of treatment.
Klaricid IV is a white to off-white caked, lyophilized powder available in vials containing Skin and soft tissue infections of mild to moderate severity: Observations from drug interaction studies using the soft gelatin capsule formulation may not be representative of the effects seen using the saquinavir hard gelatin capsule.
Clarithromycin must not be given to patients with hypokalaemia see section 4. Hypotension, bradyarrhythmias and lactic acidosis have been observed in patients taking clarithromycin and verapamil concomitantly. Uncommon With oral use epistaxis With parenteral use cardiac arrest ; dyskinesia ; haemorrhage ; loss of consciousness ; pulmonary embolism.
Most species of Gram-negative bacteria are resistant to clarithromycin because of failure to penetrate to the target.
This includes any possible side effects not listed in the leaflet. Clarithromycin should be used with caution when administered concurrently with medications that induce the cytochrome CYP3A4 enzyme see section 4.
Clarithromycin exposure was decreased by etravirine; however, concentrations of the active metabolite, OH-clarithromycin, were increased. By mouth using modified-release medicines. The pharmacokinetics of clarithromycin and the hydroxy metabolite are non-linear; steady state is achieved by day 3 of IV dosing.